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The aim was to investigate the effectiveness of glucocorticoid therapy in patients with
COVID-19. A systematic search of the literature across nine databases was conducted
from inception until 15th March 2020, following the PRISMA guidelines. Patients with a
validated diagnosis of COVID-19 and using corticosteroids were included, considering all
health outcomes. Four studies with 542 Chinese participants were included. Two studies
reported negative findings regarding the use of corticosteroids in patients with COVID-19,
i.e., corticosteroids had a detrimental impact on clinical outcomes. One study reported
no significant association between the use of corticosteroids and clinical outcomes.
However, one study, on 201 participants with different stages of pneumonia due to
COVID-19, found that in more severe forms, the administration of methylprednisolone
significantly reduced the risk of death by 62%. The literature to date does not fully
support the routine use of corticosteroids in COVID-19, but some findings suggest that
methylprednisolone could lower mortality rate in more severe forms of the condition.
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INTRODUCTION
Coronaviruses are ribonucleic acid viruses. Importantly, in humans the viruses may infect the
respiratory, gastrointestinal, hepatic, and central nervous systems (1). Infection with four of the
most common coronaviruses strains (HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1)
usually lead to mild, self-limiting upper respiratory tract infections (2). However, other
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coronaviruses, are associated with severe acute respiratory
syndrome (SARS-CoV) and the Middle East respiratory
syndrome (MERS-CoV).
In March 2020, the World Health Organization (WHO)
declared the COVID-19 outbreak a global pandemic. COVID-
19 is caused by SARS-CoV-2, a variant of coronavirus. As of 10
April 2020, over 1,500,000 confirmed cases have been diagnosed
in more than 130 countries and areas, resulting in about 93,000
fatalities thus far (3). Symptoms of infection are usually non-
specific, and include fever, cough, and myalgia, with diarrhea,
with or without the subsequent development of dyspnea (4).
Severe cases that include respiratory distress, sepsis, and septic
shock have been increasingly reported (5).
During the SARS-CoV epidemic of 2003, therapeutic systemic
corticosteroids were administered in patients who were infected
and developed severe respiratory disease. In a meta-analysis
of corticosteroid use in patients with SARS, only four studies
provided conclusive data, all indicating higher mortality (6).
One recent systematic review and meta-analysis identified
ten observational studies investigating the administration of
corticosteroids in 6,458 patients affected by influenza (7). The
review identified increased mortality in patients who were given
corticosteroids. Moreover, the length of stay in an intensive care
unit was increased, as was the rate of secondary bacterial or
fungal infection. Corticosteroids have also been investigated for
respiratory syncytial virus (RSV) in clinical trials in children
with no conclusive evidence of benefit, and are therefore not
recommended (8).
Two recent commentaries published in the Lancet between
February and March 2020 reported that corticosteroids should
not be used for the treatment of COVID-19 (9, 10). However,
these assumptions are mainly based on the findings of the meta-
analyses cited above, on disease caused by similar viruses, but not
research on COVID-19 specifically.
Therefore, the clinical, therapeutic, and side effects of systemic
glucocorticoid therapy in COVID-19 patients are currently
unclear. Given this background, the present review investigates
the effectiveness of glucocorticoid therapy in patients with
COVID-19 by applying a systematic review of the literature
currently available. The main objective is to investigate whether
there is a clinical necessity, or therapeutic justification, for the use
of systemic corticosteroids in patients with COVID-19.
METHODS
This systematic review followed the MOOSE and PRISMA
guidelines (11, 12).
Data Sources and Literature Search
Strategy
Two investigators (NV and JD) independently conducted a
literature search using Embase, PubMed, Web of Science, CNKI,
Medline, Cinahl, Toxline, and SCOPUS. Specific research in
Chinese database Wan-Fang of published and unpublished
literature was conducted by one author (LY) and checked
by another researcher (LZ). The database search was run
from database inception until 15th March 2020. All studies
reporting information regarding the use of corticosteroids in
COVID-19 were included. In PubMed, the following search
strategy was used: “(COVID-19 OR Novel Coronavirus–Infected
Pneumonia OR 2019 novel coronavirus OR 2019-nCoV OR
SARS-CoV-2) AND (cortic∗ OR “glucocorticoids” OR “steroids”
OR “corticosteroids” OR “hydrocortisone” OR “prednisone” OR
“methylprednisolone” OR “dexamethasone” OR “prednisolone”).
The strategy was then adapted for the other databases.
Conference abstracts and reference lists of included articles
were hand-searched to identify any potential additional relevant
articles. Any inconsistencies were resolved by consensus with a
third author (LS).
Study Selection
Following the PICO framework (13), we included: participants
who had a validated diagnosis of COVID-19, irrespective of
stage, or severity; intervention: use of corticosteroids (no a priori
definition of dosage or route was made); comparison: patients
affected by COVID-19 not taking corticosteroids; outcomes: all
health outcomes were included, due to the anticipated scarcity
of data. A priori, both intervention and observational data
were considered.
Data Extraction
Two independent investigators (NV and JD) extracted key
data from the included articles in a standardized Excel
database and a third independent investigator (LS) validated
the data extraction. For each article, we extracted data
regarding authors, year of publication, country, city or
region in which the study was conducted, the period of
observation, how the diagnosis of COVID-19 was obtained,
the stage of COVID-19 infection (asymptomatic forms,
pneumonia, acute respiratory distress syndrome (ARDS),
requiring intensive care unit, ICU; convalescent), sample
size included, number of males and females, mean age
and its standard deviation (or similar information such as
median and range), the percentage of people treated with
corticosteroids in the sample as a whole, and, if possible, the
route of administration and type of corticosteroid considered.
The dosage of corticosteroids used in these studies was
mainly unavailable.
Data Synthesis and Statistical Analysis
Data are reported descriptively according to the best evidence
synthesis. When possible, numerical data are reported.
RESULTS
Search Results
As shown in Figure 1, among 31 initially included studies (14 in
English and 17 in Chinese), eight were reviewed as full-text and
four finally included (14–17). Two studies were excluded since
they were commentaries (9, 10), one excluded as it was a protocol
(18), and one a letter to Editor (19).
Patients Characteristics and Main Findings
Table 1 shows the descriptive characteristics of the four included
studies. Altogether, 542 Chinese participants, mainly males
(=55.7%) of amean age of 52 years (range: 34–68), were included.
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FIGURE 1 | PRISMA flow-chart.
All the studies were conducted between the end of 2019 and
February 2020. The diagnosis of COVID-19 was made in all
the studies using reverse transcriptase-polymerase chain reaction
on throat swab samples. Three among the four studies included
pneumonia at any stage, from mild to more complicated forms,
and one convalescent patient.
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TABLE 1 | Descriptive characteristics of the studies included.
References City/region Period of observation COVID diagnosis Stage of
COVID
Sample
size
Number
of males
Mean/median age
(SD or range)
Liu et al. (17) Nine tertiary hospitals in
Hubei province
December 30, 2019–
January 24, 2020
RT-PCR on Throat
swab samples
Pneumonia 137 61 55 (16)
Wang et al. (15) Zhongnan Hospital of
Wuhan University
January 1–
January 28, 2020
RT-PCR on Throat
swab samples
Pneumonia 138 75 56 (42–68)
Wu et al. (16) Wuhan Jinyintan Hospital December 25, 2019–
January 26, 2020
RT-PCR on Throat
swab samples
Pneumonia 201 128 51 (43–60)
Ling et al. (14) Shanghai Public Health
Clinical Center
January 20, 2020–
February 10, 2020
RT-PCR on Throat
swab samples
Convalescent 66 38 44 (34–62)
COVID, coronavirus disease 2019; RT-PCR, Reverse transcriptase-polymerase chain reaction.
Table 2 summarizes the findings of the studies included.
The percentage of patients taking corticosteroids ranged from
7.6 to 44.9% of the cohorts included. Two studies (14, 15)
reported negative findings regarding the use of corticosteroids
in patients with COVID-19. Wang et al. (15) showed the group
treated with corticosteroids experience a doubled risk of being
admitted to an ICU, while in Ling et al. (14), the duration
of viral RNA for oropharyngeal swabs and feces was almost
doubled in corticosteroids group than controls. Liu et al. did not
report any benefit of the use of intravenous methylprednisolone
(30–80 mg/day) on clinical outcomes (i.e., short-term disease
progression) in 137 participants (17). Finally, Wu et al. carried
out their study among 201 participants with different stages
of pneumonia due to COVID-19, and found that, in more
severe forms (i.e., in subjects having ARDS due to COVID-
19), the administration of standard doses of methylprednisolone
significantly reduced the risk of death by 62% (16).
DISCUSSION
In this systematic review including 542 Chinese patients, we
have for the first time summarized the ultimate available
literature regarding the use of corticosteroids in the treatment
of a recent viral condition that is spreading on a global scale.
Overall, two studies reported negative findings regarding these
medications, one reported no significant association between
corticosteroids and clinical outcomes, and one concluded
that methylprednisolone was associated with a significant
reduction of mortality in patients with COVID-19 pneumonia
developing ARDS.
Since COVID-19 was first reported in December 2019, it
has attracted global attention owing to its similarity to SARS-
CoV and MERS-CoV in causing fatal respiratory disease, and its
potential for causing large-scale human infection and economic
disruption. When considering patients with SARS and MERS,
the use of corticosteroids therapy is still debated (20, 21).
Corticosteroids therapy was used in the treatment of severe
SARS because early anecdotal experience supported it, and
radiological findings, and histologic features of critically ill
patients with SARS were similar to those of patients with ARDS
(22, 23). In March 2003, China summarized its experience
in the management of SARS, and suggested that high-dose
glucocorticoids should be used if patients had a fever persisting
TABLE 2 | Main findings of the studies included.
References Percentage of
people treated with
corticosteroids
Findings regarding
corticosteroids
Liu et al. (17) 29.2 Intravenous methylprednisolone
(30–80 mg/day) did not show
significant benefits. Not numerical
data were reported
Wang et al. (15) 44.9 Glucocorticoid therapy was
associated with a greater risk of ICU
admission: 26 (72.2) vs. 36 (35.3),
p < 0.001
Wu et al. (16) 30.8 Administration of methylprednisolone
reduced the risk of death (hazard
ratio, 0.38; 95% CI, 0.20–0.72;
P = 0.003) in subjects having ARDS
for COVID 19
Ling et al. (14) 7.6 The duration of viral RNA detection
for oropharyngeal swabs and feces in
the corticosteroid treatment group
was longer than that in the
non-corticosteroid treatment group,
which were 15 vs. 8.0 days
(P = 0.013) and 20 vs. 11
days (P < 0.001).
ICU, intensive care unit; ARDS, Acute respiratory distress syndrome; COVID, coronavirus
disease 2019.
for more than 3 days, or if radiologic findings were suggestive
of persistent lung involvement or progressive deterioration (24).
One systematic review of studies on patients with SARS-CoV,
including 29 studies documenting glucocorticoid use, found 25
studies that were inconclusive regarding the role of the adjunctive
use of glucocorticoids to standard therapy, and four studies
demonstrated that the use of systemic glucocorticoids in SARS
patients may cause possible harm (6). Moreover, a prospective,
randomized double-blinded, placebo-controlled trial compared
early hydrocortisone treatment (before day seven of the illness)
with a placebo and found that early hydrocortisone therapy was
associated with a higher subsequent plasma viral load (25).
Glucocorticoid therapy was also used for critically ill patients
with MERS. In one study, hypoxemic patients with MERS-
CoV pneumonia who were not showing signs of improvement
were given glucocorticoid therapy (20). However, the study
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reported that there was no difference in 90-days mortality, and
these patients were associated with delayed MERS-CoV RNA
clearance. This finding is somewhat confirmed in our systematic
review on COVID-19, since one study reported that the duration
of viral RNA for oropharyngeal swabs and feces was almost
doubled in corticosteroids group compared to controls (14).
Among those infected with COVID-19 some develop mild
symptoms, however, a significant proportion progress to severe
ARDS and thus require intensive care (26). The use of
corticosteroids in patients presenting with ARDS of different
etiologies remains controversial owing to mixed results in the
existing literature, mainly derived from observational studies
(27). Globally, high-dose glucocorticoids is among the most
frequently used adjuncts in ARDS (17.9%) (28). Systemic
corticosteroids have long been used among critically ill patients
presenting with ARDS given their role in lowering the circulating
levels of proinflammatory mediators (29, 30). Moreover,
adequate and prolonged glucocorticoid supplementation have
proved to mitigate the Critical Illness Related Corticosteroid
Insufficiency (CIRCI), thus enhancing resolution of lung and
systemic inflammation (31). One systematic review conducted
an analysis of individual patient data from randomized trials,
and found that, compared with the placebo group, prolonged
glucocorticoid treatment improved clinical outcomes (32). A
recent individual patient data meta-analysis combined four RCTs
evaluating prolonged methylprednisolone therapy for ARDS and
reported a significant reduction in mortality, with an increase in
ventilator-free days (13 vs. 7, p < 0.001) (33).
Recent evidence suggests that a subset of patients with
severe COVID-19 may have cytokine storm syndrome (26),
which is a condition frequently related to lung involvement
(including ARDS) (34) and multi-organ failure. In order
to induce immunosuppression to antagonize virally driven
hyperinflammation, treatments with tocilizumab (IL-6 receptor
blockade) are ongoing in patients in which a hypercytokinemia
laboratory pattern is identified. In these patients, a therapeutic
role can also be hypothesized for corticosteroids (35).
Animal experiments may also provide evidence for the use
of glucocorticoids during the acute phase of severe disease
to (i) reduce inflammation, (ii) attenuate acute lung injury,
and (iii) improve survival (32). However, other studies have
failed to provide convincing evidence to prove the efficacy
of corticosteroids in decreasing the mortality of ARDS, thus
suggesting that glucocorticoid therapy is not necessary in
this condition, and may even aggravate the clinical course of
the disease. Challenging analytic issues within these studies
(including immortal time bias and indication bias from time-
varying confounding) make these results inconclusive and larger
specifically designed clinical trials are needed to clarify the
favorable and unfavorable effects for corticosteroid therapy in
ARDS patients.
The present review has summarized the current evidence
of corticosteroids on clinical outcomes in COVID-19 to
inform clinicians and policymakers on the current state of the
literature. Importantly, one study identified in this review in
patients with ARDS owing to COVID-19 infection showed that
methylprednisolone significantly decreased the risk of mortality.
It should be noted that there is currently one ongoing clinical trial
that is directly addressing this research question and its results are
eagerly awaited (18).
The present review should be interpreted in light of its
limitations. First, only four studies from China were included
and heterogeneous data were reported. More research on this
topic is needed before concrete recommendations can be made.
Second, the type and dosage of corticosteroids varied between
studies and, except in the case of Wu et al. (16), corticosteroids
were considered as only one class despite having different actions
and properties. Third, the data are based only on retrospective
findings and cohort studies are now urgently needed. Finally,
existing data comes only from China and, consequently, it is not
known if the genetic background of Chinese people may modify
the results found in the present work and in which direction.
CONCLUSIONS
In conclusion, the literature available so far does not fully
encourage the routine use of corticosteroids in COVID-19,
but some findings suggest that methylprednisolone could lower
mortality rate in more severe forms of this condition, such as
in ARDS. Findings from future clinical trials that are ongoing
are needed to better understand the role of corticosteroids
in COVID-19.
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